What drugs does P AND L make?

P AND L has 15 FDA-approved drugs including NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE.

What therapeutic areas does P AND L focus on?

P AND L focuses primarily on Infectious Disease and Cardiovascular and 1 other therapeutic areas.

← Back

Data updated: Jul 17, 2026

P AND L

Generics

Infectious Disease Cardiovascular Gastroenterology

P AND L is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.

1996

Since

Drugs

Trials

New Drugs (2yr)

Modality:

Upcoming FDA Decisions

Full Calendar →

Jul 23, 2026 — Rivoceranib + camrelizumab

Aug 10, 2026 — Oveporexton (TAK-861)

+2 more dates (Pro)

P AND L's Key Drugs

P AND L's core commercial portfolio centers on NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

Immunology

Approved 2018

P AND L's Recent FDA Approvals

P AND L secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

P AND L's Therapeutic Areas

P AND L's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%

1 drugs

Cardiovascular 33%

1 drugs

Gastroenterology 33%

1 drugs

P AND L's Top Competitors

P AND L's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, WAYLIS THERAP, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

APOTHECON specialty

Infectious Disease, Cardiovascular, Gastroenterology

WAYLIS THERAP big-pharma

Cardiovascular, Infectious Disease, Gastroenterology

Merck big-pharma

Infectious Disease, Cardiovascular

WARNER CHILCOTT big-pharma

Cardiovascular, Gastroenterology, Infectious Disease

Baxter specialty

Infectious Disease, Cardiovascular